{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:36:08Z","timestamp":1789054568917,"version":"build-2803163510"},"reference-count":47,"publisher":"The Royal Society","issue":"87","license":[{"start":{"date-parts":[[2013,10,6]],"date-time":"2013-10-06T00:00:00Z","timestamp":1381017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":["royalsocietypublishing.org"],"crossmark-restriction":true},"short-container-title":["J. R. Soc. Interface."],"published-print":{"date-parts":[[2013,10,6]]},"abstract":"<jats:p>Approximately 100 million newborn children receive Bacille Calmette\u2013Gu\u00e9rin (BCG) annually, because vaccination is consistently protective against childhood tuberculous meningitis and miliary TB. By contrast, BCG efficacy against pulmonary TB in children and adults is highly variable, ranging from 0% to 80%, though it tends to be higher in individuals who have no detectable prior exposure to mycobacterial infections, as judged by the absence of delayed-type hypersensitivity response (a negative tuberculin skin test, TST). The duration of protection against pulmonary TB is also variable, but lasts about 10 years on average. These observations raise the possibility that BCG revaccination, following primary vaccination in infancy, could be efficacious among TST-negative adolescents as they move into adulthood, the period of highest risk for pulmonary disease. To inform continuing debate about revaccination, this paper assesses the effectiveness and cost-effectiveness of revaccinating adolescents in a setting with intense transmission\u2014Cape Town, South Africa. For a cost of revaccination in the range US$1\u201310 per person, and vaccine efficacy between 10% and 80% with protection for 10 years, the incremental cost per year of healthy life recovered (disability-adjusted life years, DALY) in the vaccinated population lies between US$116 and US$9237. The intervention is about twice as cost-effective when allowing for the extra benefits of preventing transmission, with costs per DALY recovered in the range US$52\u2013$4540. At 80% efficacy, revaccination averted 17% of cases. Under the scenarios investigated, BCG revaccination is cost-effective against international benchmarks, though not highly effective. Cost-effectiveness ratios would be more favourable if we also allow for TB cases averted by preventing transmission to HIV-positive people, for the protection of HIV-negative people who later acquire HIV infection, for the possible non-specific benefits of BCG, for the fact that some adolescents would receive BCG for the first time, and for cost sharing when BCG is integrated into an adolescent immunization programme. These findings suggest, subject to further evaluation, that BCG revaccination could be cost-effective in some settings.<\/jats:p>","DOI":"10.1098\/rsif.2013.0365","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T05:41:38Z","timestamp":1375249298000},"page":"20130365","update-policy":"https:\/\/doi.org\/10.1098\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Making wider use of the world's most widely used vaccine: Bacille Calmette\u2013Gu\u00e9rin revaccination reconsidered"],"prefix":"10.1098","volume":"10","author":[{"given":"Christopher","family":"Dye","sequence":"first","affiliation":[{"name":"World Health Organization, Avenue Appia, CH1211 Geneva 27, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2013,10,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60177-4"},{"key":"e_1_3_3_3_2","first-page":"229","article-title":"Statement on BCG revaccination for the prevention of tuberculosis","volume":"70","author":"World Health Organization","year":"1995","journal-title":"Wkly Epidemiol. Rec."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001012"},{"key":"e_1_3_3_5_2","first-page":"27","article-title":"BCG vaccine","volume":"79","author":"World Health Organization","year":"2004","journal-title":"Wkly Epidemiol. Rec."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68507-3"},{"key":"e_1_3_3_7_2","first-page":"1","volume-title":"International union against tuberculosis","author":"Rieder HL","year":"2002"},{"key":"e_1_3_3_8_2","unstructured":"Mangtani P et al. Submitted. Protection by BCG against tuberculosis: a systematic review and meta-regression analysis of data from randomised controlled trials."},{"key":"e_1_3_3_9_2","first-page":"119","article-title":"Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India","volume":"123","author":"Narayanan PR","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5974"},{"key":"e_1_3_3_11_2","first-page":"1171","article-title":"Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil","volume":"9","author":"Barreto ML","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.17.2086"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.17.2127"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)02166-6"},{"key":"e_1_3_3_15_2","first-page":"717","article-title":"Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong","volume":"5","author":"Leung CC","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.05.023"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67534-4"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.140186"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0974OC"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202208"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.02.001"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.059"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir951"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03199-7"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh001"},{"key":"e_1_3_3_26_2","first-page":"255","article-title":"The development of clinical tuberculosis following infection with tubercle bacilli. I. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands","volume":"63","author":"Sutherland I","year":"1982","journal-title":"Tubercle"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268897007917"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir162"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90748-X"},{"key":"e_1_3_3_30_2","first-page":"103","article-title":"Comments on the new analysis of the Chingleput BCG trial","volume":"123","author":"Rook GAW","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_3_31_2","first-page":"573","article-title":"Annual risk of tuberculous infection in the northern zone of India","volume":"81","author":"Chadha V","year":"2003","journal-title":"Bull. World Health Organ."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2008.02213.x"},{"key":"e_1_3_3_33_2","first-page":"406","article-title":"Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa","volume":"14","author":"Wood R","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025098"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-220"},{"key":"e_1_3_3_36_2","volume-title":"Immunization surveillance, assessment and monitoring","author":"World Health Organization","year":"2013"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-156"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(94)90163-5"},{"key":"e_1_3_3_39_2","first-page":"289","volume-title":"Disease control priorities in developing countries","author":"Dye C","year":"2006","edition":"2"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","volume-title":"World development indicators","author":"The World Bank","DOI":"10.1596\/978-1-4648-0484-7_world_development_indicators"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38645.660093.68"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-493"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70285-7"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60137-3"},{"key":"e_1_3_3_45_2","volume-title":"Global tuberculosis control: WHO report 2012","author":"World Health Organization","year":"2012"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200606-759OC"},{"key":"e_1_3_3_47_2","first-page":"193","article-title":"Revised BCG vaccination guidelines for infants at risk for HIV infection","volume":"82","author":"World Health Organization","year":"2007","journal-title":"Wly Epidemiol. Rec."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2052"}],"container-title":["Journal of The Royal Society Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rsif.2013.0365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/full-xml\/10.1098\/rsif.2013.0365","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rsif.2013.0365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:24:39Z","timestamp":1778621079000},"score":1,"resource":{"primary":{"URL":"http:\/\/royalsocietypublishing.org\/rsif\/article\/72396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,6]]},"references-count":47,"journal-issue":{"issue":"87","published-print":{"date-parts":[[2013,10,6]]}},"alternative-id":["10.1098\/rsif.2013.0365"],"URL":"https:\/\/doi.org\/10.1098\/rsif.2013.0365","relation":{},"ISSN":["1742-5689","1742-5662"],"issn-type":[{"value":"1742-5689","type":"print"},{"value":"1742-5662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,6]]},"assertion":[{"value":"2013-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}